[HTML][HTML] Histone deacetylases modulate resistance to the therapy in lung cancer
E Contreras-Sanzón, H Prado-Garcia… - Frontiers in …, 2022 - frontiersin.org
The acetylation status of histones located in both oncogenes and tumor suppressor genes
modulate cancer hallmarks. In lung cancer, changes in the acetylation status are associated …
modulate cancer hallmarks. In lung cancer, changes in the acetylation status are associated …
Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon EGFR mutations: Real‐world data from Taiwan
JWC Chang, CY Huang, YF Fang, CF Chang… - Thoracic …, 2023 - Wiley Online Library
Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are the
standard treatment for patients with non‐small cell lung cancer (NSCLC) harboring EGFR …
standard treatment for patients with non‐small cell lung cancer (NSCLC) harboring EGFR …
[HTML][HTML] Risk stratification using a novel nomogram for 2190 EGFR-mutant NSCLC patients receiving the first or second generation EGFR-TKI
JWC Chang, CY Huang, YF Fang, CF Chang, CT Yang… - Cancers, 2022 - mdpi.com
Simple Summary No comprehensive and simple prognostic model based on pretreatment
factors exists for patients with epidermal growth factor receptor mutation-positive (EGFRm+) …
factors exists for patients with epidermal growth factor receptor mutation-positive (EGFRm+) …
[HTML][HTML] Impact of T790M mutation status on Later-Line osimertinib treatment in non-small cell lung cancer patients
YJ Tang, JWC Chang, CF Chang, CY Huang, CT Yang… - Cancers, 2022 - mdpi.com
Simple Summary Osimertinib is a third-generation epidermal growth factor receptor tyrosine
kinase inhibitor (EGFR-TKI) designed to overcome acquired T790M resistance mutations in …
kinase inhibitor (EGFR-TKI) designed to overcome acquired T790M resistance mutations in …
Real-world Afatinib Outcomes in Advanced Non–small Cell Lung Cancer Harboring EGFR Mutations
CH Chen, JWC Chang, CF Chang… - Anticancer …, 2022 - ar.iiarjournals.org
Background/Aim: Afatinib is a standard treatment for patients with advanced non–small cell
lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations …
lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations …
Sequential treatment in advanced non–small cell lung cancer harboring EGFR mutations
PC Hsu, JWC Chang, CF Chang… - Therapeutic …, 2022 - journals.sagepub.com
Background: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are
standard treatments for advanced EGFR-mutated non–small cell lung cancer (NSCLC) …
standard treatments for advanced EGFR-mutated non–small cell lung cancer (NSCLC) …
First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study
S Igawa, T Fukui, M Kasajima, T Ono, T Ozawa… - Investigational New …, 2022 - Springer
Objective. The clinical outcomes of poor performance status (PS) patients with epidermal
growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who are treated …
growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who are treated …
[HTML][HTML] Comprehensive analysis of m5C-related lncRNAs in the prognosis and immune landscape of hepatocellular carcinoma
Q Lu, L Liu, S Wang, Q Zhang, L Li - Frontiers in Genetics, 2022 - frontiersin.org
5-Methyladenosine (m5C) is a type of epigenetic modification involved in the progression of
various cancers. To investigate the role of m5C-related long non-coding RNAs (lncRNAs) in …
various cancers. To investigate the role of m5C-related long non-coding RNAs (lncRNAs) in …
[HTML][HTML] Comparison of different tyrosine kinase inhibitors for treatment of poor performance status patients with EGFR-mutated lung adenocarcinoma
CE Wu, CF Chang, CY Huang, CT Yang, CHS Kuo… - Cancers, 2022 - mdpi.com
Simple Summary Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)
are standard treatments in patients with EGFR-mutated lung adenocarcinoma. However, the …
are standard treatments in patients with EGFR-mutated lung adenocarcinoma. However, the …
The survival after discontinuation of EGFR‐TKIs due to intolerable adverse events in patients with EGFR‐mutated non–small cell lung cancer
JWC Chang, CF Chang, CY Huang, CT Yang… - Thoracic …, 2023 - Wiley Online Library
Background Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) are
standard treatments for advanced non–small cell lung cancer (NSCLC) patients harboring …
standard treatments for advanced non–small cell lung cancer (NSCLC) patients harboring …